

BONESUPPORT HOLDING AB (publ) – Q2 2018 Interim Report – invitation to conference call and webcast

Lund, Sweden, 13.00 CET, 23 July 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids will publish its Q2 2018 Interim Report on Thursday 26 July 2018 at 8am CET.

The Company will also host a conference call and an online presentation on the same day at 2pm CET.

The dial-in numbers for the conference call are: UK: +44 2030089809

SE: +46 856642665

US: +1 8558315945

The presentation will also be webcast and can be accessed from the following web address: <https://financialhearings.com/event/10858>

Hosts: Emil Billbäck, CEO, and Björn Westberg, CFO

For more information contact:

Emil Billbäck, CEO

+46 (0) 46 286 53 70

Björn Westberg, CFO

+46 (0) 46 286 53 60

ir@bonesupport.com

Citigate Dewe Rogerson

Pip Batty, David Dible, Shabnam Bashir, Isabelle Andrews

+44 (0)20 7282 1022

bonesupport@citigatedewe Rogerson.com

About BONESUPPORT™

BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs directly into the bone void.

BONESUPPORT's bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company's novel and proprietary technology platform.

The Company's products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.

BONESUPPORT's total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%.

The Company's research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.

In addition, BONESUPPORT is looking at opportunities to expand its product offering in the US and has entered into a strategic agreement with Collagen Matrix Inc. to market and distribute products that are complementary to CERAMENT BVF.

BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker "BONEX" (ISIN code: SE0009858152). Further information is available at www.bonesupport.com

*CERAMENT G: Not available in the United States, for investigational use only.

CERAMENT V: Not available in the United States.

BONESUPPORT™ and CERAMENT® are registered trademarks.

The information was submitted for publication, through the agency of the contact person set out above, at 13.00 CET on 23rd July 2018.